MRI Compatible Electrode Catheter System

Information

  • Research Project
  • 7404682
  • ApplicationId
    7404682
  • Core Project Number
    R44HL072639
  • Full Project Number
    2R44HL072639-02
  • Serial Number
    72639
  • FOA Number
    PA-07-80
  • Sub Project Id
  • Project Start Date
    7/1/2003 - 21 years ago
  • Project End Date
    2/28/2010 - 14 years ago
  • Program Officer Name
    BUXTON, DENIS B.
  • Budget Start Date
    3/15/2008 - 16 years ago
  • Budget End Date
    2/28/2009 - 15 years ago
  • Fiscal Year
    2008
  • Support Year
    2
  • Suffix
  • Award Notice Date
    3/4/2008 - 16 years ago

MRI Compatible Electrode Catheter System

[unreadable] DESCRIPTION (provided by applicant): Atrial fibrillation and ventricular tachyarrhythmias occurring in patients with structurally abnormal hearts are the most important arrhythmias in contemporary cardiology.1-3 they represent the most frequently encountered tachycardias, account for the most morbidity and mortality, and, despite much progress, remain therapeutic challenges. Invasive studies of the electrical activity of the heart (electrophysiologic studies) are often used in the diagnosis and therapy of arrhythmias and many arrhythmias can be cured by selective destruction of critical electrical pathways with radiofrequency (RF) catheter ablation. Attempts at applying ablation to atrial fibrillation and ventricular tachycardia have been made. Success has been limited, however, by the long time duration of procedures, resulting from the difficulty of creating continuous linear lesions in a setting where areas of ablated myocardium cannot be directly visualized. Continuous linear lesions, without gaps, can block critical arrhythmogenic circuits and reduce the amount of electrically contiguous arrhythmoginic substrate, thereby eliminating arrhythmias. We hypothesize that magnetic resonance imaging (MRI), with MRI-compatible diagnostic and therapeutic systems; can allow electrophysiology studies and catheter ablation to be performed without x-ray radiation. We also hypothesize that this technology will provide the ability to visualize ablation lesions, which should greatly simplify production of continuous linear lesions, and should improve the effectiveness of ablation procedures in general. In addition to electrophysiology, these methods may be applicable to guiding other diagnostic and therapeutic techniques. In Phase I, we completed a prototype steerable ablation catheter that has allowed us to target any area of the endocardial surface of the heart. We also developed integral filters for protecting the catheters from excessive heating during MR imaging. We tested the prototype catheters in animals to show that electrophysiology studies can be done under MR guidance alone, that lesions can be produced and imaged, that linear lesions can be produced, and that MRI has sufficient resolution to allow detection of significant gaps in the lesions. In Phase II, we will develop, test, and prepare for manufacturing and marketing an improved, clinical-grade version of the ablation system, and apply for FDA approval for testing the technology. The improved, clinical-grade catheter system will incorporate all capabilities previously tested individually. The improved catheter system will both ablate cardiac tissue and sense cardiac activity. The improved catheter will also have improved filtering and shielding to allow all current clinical MRI pulse sequences to be used for imaging. Further, the improved catheter system will have sensors incorporated into the tip of the catheters to allow accurate determination of the position of the catheter tip, enabling real-time manipulation of the imaging plane to always include the catheter tip. Finally, the improved catheter system will incorporate temperature sensors for monitoring ablation temperatures at the catheter tip. Rhythm abnormalities of the heart, where the heart beats too fast, affect millions of people in the United States. These abnormalities can cause substantial symptoms and/or death, and some can be cured by cauterizing (ablating) a small portion of the heart. Methods are being developed to use the real-time and high quality imaging of Magnetic Resonance Imaging to improve substantially the safety and efficacy of these ablations, as well as extend these methods to procedures involving other organ systems. [unreadable] [unreadable] [unreadable]

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R44
  • Administering IC
    HL
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    917899
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:917899\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    IMRICOR MEDICAL SYSTEMS, INC.
  • Organization Department
  • Organization DUNS
    787489140
  • Organization City
    Burnsville
  • Organization State
    MN
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    55337
  • Organization District
    UNITED STATES